



A low abundance of genus *Bacteroides* in gut microbiota is negatively correlated with blood phenylalanine levels in Uygur patients with phenylketonuria

Yajie Su^{1,2}, Qiaolibang Shadike², Mingbang Wang³, Haili Jiang², Wanying Liu², Jingfang Liu², Rena Tuerdi², Wenhao Zhou^{1,4}, Long Li^{2,5}

¹Department of Neonatology, Children's Hospital of Fudan University, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China;

²Department of Neonatology, Children's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China; ³Centre for Molecular Medicine, Children's Hospital of Fudan University, Shanghai, China; ⁴Shanghai Key Laboratory of Birth Defects, Pediatrics Research Institute, Shanghai, China; ⁵Department of Neonatology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China

Contributions: (I) Conception and design: L Li, W Zhou; (II) Administrative support: L Li, W Zhou; (III) Provision of study materials or patients: Y Su, L Li; (IV) Collection and assembly of data: Q Shadike, H Jiang, W Liu, J Liu, R Tuerdi; (V) Data analysis and interpretation: Y Su, M Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Long Li. Children's Hospital of Xinjiang Uygur Autonomous Region, 393 Aletai Road, Urumqi 830001, China.

Email: lilong65@126.com; Wenhao Zhou. Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai 201102, China.

Email: zhouwenhao@fudan.edu.cn.

Background: A low-phenylalanine (Phe) diet affects the metabolism and diversity of gut microbial communities in children with phenylketonuria (PKU). Our study examined gut microbiota characteristics and metabolic pathways, and their correlations with clinical phenotypes in a high-incidence population.

Methods: We assessed clinical phenotypes and gut microbiota by 16S ribosomal RNA (rRNA) sequencing, and performed a correlation analysis between phenotype and gut microbiota in a PKU group (n=11) and a healthy group (n=11).

Results: The PKU group had significantly lower microbiota diversity than the healthy group ($P_{\text{shannon}}=0.014$). Phylum-level composition differed significantly between the PKU and healthy groups (*Firmicutes*: 44.3% vs. 43.1%; *Actinobacteria*: 25.9% vs. 3.3%; *Bacteroidetes*: 16.6% vs. 53.2%; and *Proteobacteria*: 10.9% vs. 0.12%, respectively). Further, a significantly decreased level of genus *Bacteroidetes* ($P<0.0001$) in the PKU group was negatively correlated with blood Phe level ($P=0.014$). The microbial function prediction of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways exhibited a decreased ability of glycan degradation and glutamate metabolism in the PKU group.

Conclusions: Our findings revealed that genus *Bacteroides* was not only in extremely low abundance in the PKU group, but was also negatively correlated with blood Phe level. The remarkable capability of genus *Bacteroides* to use complex recalcitrant glycans may be the main reason for the decreased ability of glycan degradation in the PKU group.

Keywords: Phenylketonuria (PKU); gut microbiota; 16S ribosomal RNA sequencing (16S rRNA sequencing); clinical phenotype; Uygur

Submitted Aug 13, 2021. Accepted for publication Oct 09, 2021.

doi: 10.21037/tp-21-426

View this article at: <https://dx.doi.org/10.21037/tp-21-426>

Introduction

Phenylketonuria (PKU; OMIM 261600) is a classical metabolic disorder characterized by high-plasma phenylalanine (Phe) concentration owing to pathogenic variations in the *PAH* gene. The first line of treatment is a life-long low-Phe diet, a lack of which results in serious neurocognitive deficits, mental health issues, and behavioral concerns (1). However, despite several decades of research, unresolved challenges remain in relation to this genetic metabolic disorder. Adherence to low-Phe diet progressively decreases after adolescence (2). Additionally, some patients remain at risk of mood disorders, anxiety, and attentional disorders (3).

Currently, few treatment options exist to reduce and maintain acceptable Phe levels. However, in addition to well-known treatable factors, such as chaperone therapy with sapropterin, Phe ammonia lyase enzyme substitution therapy, and supplementation with large neutral amino acids (LNAA), there is increasing interest in the contribution of the gut microbiota to disease, given their contribution to essential functions, such as energy harvesting, host nutrition, and immunomodulation (4). Diet-related gut microbiota alterations in PKU are well known (5,6). These two studies reported that *Bacteroidetes* and *Firmicutes* were the dominant phyla in the PKU and control groups and mild hyperphenemia group, respectively. Further, they found major differences in the phylum *Firmicutes*. Notably, a particularly divergent response in glucose and amino acid metabolism was observed between the affected and control groups. Unlike children with PKU, Mancilla *et al.* (7) reported a significant differences in the abundance of specific bacterial groups in adult PKU patients. But the same was that both adults and children are involved in the abnormality of the glucose metabolism pathway.

Based on the latest available data, a total of 3 studies involving the gut microbiome with population of PKU (two children and one adults). Unlike the previous studies, our samples were Uyghur children with high incidence of PKU at 1 in 5,230 children (8,9). In addition, the population consumes a high-Phe diet, including meat, pasta, and all types of nuts. It is exactly opposite with the principles of dietary treatment for PKU. Thus, this study had three aims: (I) to determine the characteristics of gut microbiota in Uyghur patients with PKU; (II) to examine the correlations between these characteristics and clinical phenotypes of PKU using 16S ribosomal RNA

(rRNA) sequencing; and (III) to compare the microbiota composition of PKU patients to that of healthy individuals. We present the following article in accordance with the MDAR reporting checklist (available at <https://dx.doi.org/10.21037/tp-21-426>).

Methods

Study population and sample collection

This observational study was approved by the Ethics Board of the People's Hospital of Xinjiang Uyghur Autonomous Region (KY2021031018). All patients with PKU were recruited from the Neonatal Disease Screening Centre of the People's Hospital of Xinjiang Uyghur Autonomous Region and written informed consent was obtained from the parents of the participants for the publication of this study. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). A sex-, nation-, and age-matched control group of healthy children without PKU were collected from the Child Healthcare Department. To be eligible for inclusion in the PKU group, participants had to meet the following inclusion criteria: (I) have an established diagnosis of PKU; (II) accept low-Phe dietary treatment; and (III) be unrelated to other children with PKU. Individuals were excluded from both groups if they met any of the following exclusion criteria: (I) had a neurological abnormality, congenital malformation, endocrine disorder, chronic liver disease, or chronic or acute intestinal diseases; and/or (II) had been treated with antibiotics or probiotics and prebiotics (including glycomacropeptide) at any time in the 3 months preceding the study.

The following clinical parameters were evaluated: (I) sex; (II) pre-treatment Phe level; (III) current age, weight, and height; and (IV) time from birth to diagnosis. Body mass index (BMI) was calculated for all participants, and a standard BMI range according to the WHO 2009 standards was used (10). The following laboratory parameters were evaluated: the plasma levels of 11 amino acids, including Phe, tyrosine (Tyr), and free carnitine (C0). These parameters were determined using high performance liquid chromatography. The serum levels of 25-hydroxyvitamin D₃ [25(OH)D₃], macronutrients (carbohydrates, proteins, and lipids), amino acids, and mineral intake were calculated through a 72 h-dietary recall questionnaire. The daily intake ranges of proteins, lipids, and carbohydrates were calculated according to the *Encyclopedia of Nutrition Science* (11). Gut

samples were collected using a stool collection kit consisting of a sterile container with solution, and a sterilized spatula (Jingyun Biotechnology Co., Ltd., Shanghai, China). The stool samples were stored at normal temperature.

The pre-treatment Phe level of the control participants ranged from 20–120 $\mu\text{mol/L}$. While those of patients with PKU on a Phe-restricted diet ranged from 120–360 $\mu\text{mol/L}$. The recommended daily Phe intake for patients with PKU in our study was 135–330 mg according to guidelines for Chinese populations (12).

DNA isolation and PCR amplification

Microbial community genomic DNA was isolated from gut samples by Kit of E.Z.N.A. Soil DNA Kit (Omega Bio-tek, Norcross, GA, USA) according to the instructions. The isolated DNA was electrophoresed on 1% agarose gel, using a NanoDrop 2000 UV-vis spectrophotometer (Thermo Scientific, Wilmington, DE, USA) to identify the concentration and purity of DNA. Using GeneAmp 9700 polymerase chain reaction (PCR) thermal cycler (Applied Biosystems, Foster City, CA, USA) to amplify the hypervariable region (V3–V4) of the bacterial 16S rRNA gene with the primer pair 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R (5'-GGACTACHVGGGTWTCTAAT-3'). PCR reactions were prepared in 20 μL contained 5 \times TransStart FastPfu buffer (4 μL), 2.5 mM dNTPs (2 μL), 5 μM of forward primer (0.8 μL), 5 μM of reverse primer (0.8 μL), TransStart FastPfu DNA Polymerase (0.4 μL), template DNA (10 ng), and ddH₂O for a final volume. Thermocycler conditions: an initial denaturation at 95 °C for 3 min, followed by 27 cycles at 95 °C for 30 s, annealing at 55 °C for 30 s, an extension at 72 °C for 45 s, and a final extension at 72 °C for 10 min. PCR reactions were performed in triplicate. PCR products were separated by electrophoresis on 2% agarose gels and purified using an AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA) and quantified using a Quantus Fluorometer (Promega, Madison, WI, USA).

16S rRNA gene sequencing

Purified amplicons were pooled in equimolar quantities and paired-end sequenced was performed using a MiSeq PE300 or NovaSeq PE250 (Illumina, San Diego, CA, USA) in accordance with the standard protocols by Majorbio Bio-

Pharm Technology Co., Ltd. (Shanghai, China).

Sequencing data analysis

We used fastp (version 0.20.0) to demultiplex and filter the raw sequencing reads (13), and merged using FLASH version 1.2.7 (14). The 300 bp reads were truncated at any site receiving an average quality score of <20 over a 50-bp sliding window, and truncated reads shorter than 50 bp and those containing ambiguous characters were discarded. Only overlapping sequences longer than 10 bp were assembled according to their overlapping sequence. These sequences were clustered into Operational Taxonomic Unit (OTU) at a 97% similarity cutoff (15) followed by UPARSE version 7.1. OTU—representing sequence was analyzed using the ribosomal database project (RDP) Classifier version 2.2 (16) against a 16S rRNA database, such as Silva v132, with a confidence threshold of 0.7.

Statistical analysis

Comparisons of linear relationship between phenotypes and gut microbiota composition was performed using the lm function in R's regression analysis package. For evaluating Spearman-rank correlation analysis between phenotype and microbiota pathways, the cor and cor.test functions in the R package was performed. False discovery rate (FDR)-corrected P values <0.05 and Spearman correlation coefficient absolute values >0.3 were considered as significant.

Results

Participant characteristics

Of the 11 patients who completed the study, 7 were female. Patients' ages ranged from 10 months to 8 years and 3 months, and patients had a BMI of $16.36\pm 0.35 \text{ kg/m}^2$, and a mean pre-treatment plasma Phe level of $986.01\pm 168.19 \mu\text{mol/L}$. All patients were on a low-Phe- diet supplemented with a metabolic formula (protein substitute) without prebiotics, and no one received tetrahydrobiopterin (BH₄), LNAA-, or glycomacropeptide-based treatment. The mean plasma Phe level on the day on which the blood samples were drawn was $481.46\pm 121.87 \mu\text{mol/L}$, and the mean daily intake of Phe was $577.72\pm 127.09 \text{ mg/d}$. *Table 1* summarizes the values for other blood indicators and nutrients from daily intake (see available online: <https://>

Table 1 Characteristics of 11 patients with PKU

No.	Sex	Age (months)	BMI (kg/m ²)	Age at diagnosis (days)	Pre-treatment Phe (μmol/L)	Blood sample		Daily intake		
						25(OH)D ₃	Phe (μmol/L)	Phe (mg)	Protein (g)	Carbohydrate (g)
Standard	-	-	15.8–17	-	20–120	>30	120–360	135–330	20–40	60–120
1	Female	75	15.42	93	776.4	21.89	240.29	864.37	42.47	215.3
2	Female	14	17.91	90	418.2	29.48	237.65	905.33	54.67	276.87
3	Female	78	15.47	288	865.8	24.56	230.33	729.33	35.53	190.47
4	Female	51	16.49	64	1,694.4	33.68	691.99	127	26.17	191
5	Male	10	17.53	57	888.6	60.52	272.46	89.67	16.2	73.43
6	Male	35	16.33	330	1,680	18.32	1,581.9	232.67	29.87	179.37
7	Female	100	17.36	890	1,655.4	17.48	480.88	200.67	28.6	162.4
8	Male	67	15	138	1,582.8	23.08	654.87	102.5	20.73	144.93
9	Male	19	16.77	141	432.6	20.03	168.36	963.67	36.9	232.27
10	Female	43	14.35	284	416.4	33.65	351.67	1,033.67	35.1	207.13
11	Female	47	17.35	122	435.6	25.5	385.69	1,106	41.8	242.83
Mean ± SEM	-	49±8.70	16.36±0.35	227±72.34	986.01±168.19	28.02±3.65	481.46±121.87	577.72±127.09	33.46±3.26	192.36±16.37

PKU, phenylketonuria; BMI, body mass index; Phe, phenylalanine; 25(OH)D₃, 25-hydroxyvitamin D₃; SEM, standard error of the mean.




Figure 1 Altered gut microbiota composition in the PKU and control groups. (A,B) Alpha-diversity analysis of control participants (blue) and patients with PKU (red) using (A) Shannon and (B) Chao1 value. A higher value indicates greater community diversity. Note that a significant difference in the diversity of microbial communities between the groups was observed on the basis of the Shannon value ($P=0.014$). (C,D) Beta-diversity analysis. PCoA of (C) unweighted and (D) weighted UniFrac distances. PKU, phenylketonuria; PCoA, principal coordinate analysis.

cdn.amegroups.cn/static/public/tp-21-426-1.xlsx).

Comparison of ecological diversity of gut microbiota

After filtering reads by removing sequencing artifacts, a total of 722,283 high-quality sequences with an average of 16,186 sequences per sample were retained. The alpha-diversity analysis revealed no significant differences between the PKU and control groups based on the Ace ($P=0.95$) and Chao1 ($P=0.8$) indices; however, significant differences were found with the Simpson ($P=0.04$) and Shannon ($P=0.014$) indices, which implies that the control group had a higher diversity of gut microbiota than the PKU group (see *Figure 1A,1B*). Additionally, the beta-diversity analysis showed that the

structure of the fecal microbiota of the PKU group differed to that of the control group according to both unweighted and weighted UniFrac distances (see *Figure 1C,1D*).

Comparison of gut microbiota composition

At the phylum level, we detected more than 13 known types of bacteria, the most populous being *Firmicutes* (44.3%), *Actinobacteria* (25.9%), *Bacteroidetes* (16.6%), and *Proteobacteria* (10.9%) in the PKU group, and *Bacteroidetes* (53.2%), *Firmicutes* (43.1%), *Actinobacteria* (3.3%), and *Proteobacteria* (0.12%) in the control group. The bacterial abundance between the two groups differed significantly ($P_{Actinobacteria}=0.009$, $P_{Bacteroidetes}<0.001$, and $P_{Proteobacteria}=0.042$),




Figure 2 Analysis of bacterial composition at different levels and abundance of key bacteria. (A) Bacterial abundance at the phylum level. (B) Relative bacterial abundance at the genus level. (C) Genus-level bacterial abundance for phylum *Bacteroides*. The histogram shows bacterial abundance in all samples and differences between the two groups. (D) Bacterial abundance of the 10 most populous genera of the phylum *Collinsella*. The histogram shows bacterial abundance in all samples and differences between the two groups. ***, indicate P value smaller than 0.05 compared in two groups.

except for that of *Firmicutes* ($P_{Firmicutes}=0.86$) (see Figure 2A). Next, we chose the most populous bacteria of each group for the genus-level analysis. In the PKU group, the most populous genera were *Bifidobacterium* (19.7%), *Prevotella* (11.5%), *Subdoligranulum* (10.7%), and *Faecalibacterium* (8.4%), whereas *Bacteroides* (36.6%), *Prevotella* (12.5%), *Faecalibacterium* (11.3%), and *Bifidobacterium* (3.2%) were the most populous in the control group (see Figure 2B). Further, we found that the abundance of *Bacteroides* (2.7% vs. 36.6%; $P<0.001$) and *Collinsella* (3.38% vs. 0.09%; $P=0.002$) differed significantly between the PKU and control groups (see Figure 2C,2D). The composition of gut microbiota for each child at the phylum and genus level is presented in Figure S1, and the differences in

gut microbiota between the two groups are represented graphically in Figure 3.

Microbial function prediction between the groups

On the basis of the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analysis, we observed at least 20 differentially abundant bacterial functions related to metabolism between the PKU and control groups (all $P<0.05$). We found that all samples of the PKU group were significantly decreased in the streptomycin biosynthesis and glycan degradation. In addition, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis predicted a decrease in glutamate




Figure 3 LDA score distribution and evolutionary branch diagram. (A) Bar chart showing significant differences in bacterial abundance using a preset LDA score of >2.0 , which indicates a significant difference. The red bars in the histogram represent the PKU group; the green bars represent the control group. The length of each bar represents bacterial abundance with significant differences between the two groups. (B) Cladogram showing bacterial abundance in the PKU and control groups. The circles radiating outward represent the classification level from phylum to genus in which the innermost circle represents the kingdom. Each small circle at a classification level represents a classification at that level; the diameter of a circle represents the magnitude of the relative abundance. The yellow circles indicate no significant difference in bacterial abundance between groups. The red and green circles indicate microbial groups populous in the PKU and control group, respectively. LDA, linear discriminant analysis; PKU, phenylketonuria.

metabolism in the PKU group (see *Figure 4*).

Associations between clinical phenotype and microbiota at the genus level

The correlations between the clinical phenotype and gut bacteria of our PKU cohort are summarized in *Table 2* and available online: <https://cdn.amegroups.cn/static/public/tp-21-426-2.xlsx>. We found a strong negative correlation between the genus *Bacteroides* and blood Phe level ($P=0.014$); this bacterium was the least populous in the PKU group. The genera *Agatbobacter* and *Fusicatenibacter* had low abundance and were associated with neurological abnormalities in the PKU group ($P=0.005$ and $P=0.006$, respectively). We also found that the genus *Prevotella* was associated with the daily intake of various nutrients, specifically, Phe, calories, protein, fat, and fiber.

Discussion

Our patients were Uyghurs, who had distinct culture

characteristics driven by the ancient Silk Road, an important trade route that connected culture and trade among China, Europe, and Asia (8). This ethnic population has a high incidence of PKU and has distinctly different eating habits to those of the Han population in China. Thus, we sought to determine characteristics of the gut flora of individuals with PKU from this population.

In this study, we used a safe, non-invasive method to collect stool samples from patients with PKU and healthy control individuals, and found that the diversity of microbiota in patients with PKU was significantly decreased compared to that of control participants. Ecological theories predict that a decreased diversity of gut microbial significantly limits the ability of the microbiome to withstand major shifts, potentially leading to alternate, diseased, or stable states (17,18). In contrast to the control group and findings of previous studies (5,6), in the present study, *Firmicutes* (44.3%) and *Actinobacteria* (25.9%) were the most populous phyla in the PKU group. In the healthy control group, *Firmicutes* and *Bacteroidetes* accounted for more than 90% of the gut microbiome, followed by minor




Figure 4 KEGG pathway heatmap of the PKU and control groups. The top row represents study participants in red (PKU) or blue (control), and each subsequent row represents a different metabolic pathway. The relative intensity of the biosynthesis level is indicated in red and blue; a darker red or blue indicates a more pronounced increase or decrease, respectively. KEGG, Kyoto Encyclopedia of Genes and Genomes; PKU, phenylketonuria.

abundances of *Actinobacteria* and *Proteobacteria*. We speculate that this is a common effect of dietary habits and disease itself. There may be several reasons for these differences.

First, in our study, the genus *Collinsella*, which belongs to the phyla *Actinobacteria*, was significantly more populous in the PKU group. Studies have shown that low dietary fiber intake increases the abundance of *Collinsella* in the gut microbiome (19-21). This finding is consistent with the eating pattern of the Uyghur population, who prefer to consume meat and wheat-based foods (8). Second, we followed-up these patients of PKU who have high abundance of genus *Bifidobacterium*. We found six of them still had breast milk sometimes even they were more than 2 years. This consistent with the features of longer breastfeeding time of Uyghur mothers (22). In addition, we found that the genus *Bacteroides* were significantly lower in our PKU cohort. This was the main reason for the reduced abundance of phyla *Bacteroidetes*, and lower abundance of *Bacteroidetes* was negatively correlated with blood Phe level in our affected cohort. There is increasing evidence that *Bacteroides* have a remarkable capability to use complex recalcitrant glycans, and thus may have the capability to use diverse carbon sources by acquiring enzymes via

heterologous gene transfer events in the gut environment (23,24). This reasonably explains why the ability of glycan degradation in the PKU group was decreased as predicted in the KEGG pathway analysis (see Figure 4). Additionally, this result is also in line with previous reports that the daily glycemic index is higher in children with PKU (5,6). However, the increased glucose in these studies may be caused by phyla *Firmicutes*, whereas ours may be caused by phyla *Bacteroidetes*.

Theoretically, genus *Prevotella* (belong to phylum *Bacteroidetes*) should be highly abundant in children who consumed diets with high amounts of plant polysaccharides and fiber, lower in animal protein and saturated fats (25,26), which similar with the dietary pattern of children with PKU. Considering that children with PKU are in the growth and development period, adequate protein intake must be ensured. The patients need to restrict the intake of natural protein, an important source of protein is the amino acid formula of free-Phe. After absorbing protein in small intestine, specific carbohydrates which was lacking oligosaccharides, lactose polymers into the large intestine (11). The carbohydrates reduce the abundance of *Lactic acid bacteria*, *Clostridium butyricum* and *Prausnitzii* (27),

Table 2 Correlations between PKU clinical phenotypes and bacterial abundance

Category	Actinobacteria		Bacteroidetes			Firmicutes				Proteobacteria
	<i>Bifidobacterium</i>	<i>Collinsella</i>	<i>Bacteroides</i>	<i>Prevotella</i>	<i>Agathobacter</i>	<i>Fusicatenibacter</i>	<i>Roseburia</i>	<i>Terrisporobacter</i>		
Clinical information										
Neurological abnormality	0.56	0.85	0.333	0.704	0.005*	0.006*	0.583	0.322	0.257	
Blood sample										
25(OH)D ₃	0.189	0.832	0.611	0.852	0.353	0.852	0.016*	0.366	0.361	
Plasma Phe	0.79	0.957	0.014*	0.649	0.31	0.325	0.749	0.574	0.295	
Plasma Tyr	0.65	0.083	0.852	0.183	0.527	0.957	0.2	0.935	0.361	
Plasma C0	0.417	0.055	0.16	0.094	0.957	0.169	0.142	0.967	0.877	
Daily intake										
Phe	0.484	0.831	0.79	0.008*	0.718	0.729	0.611	0.093	0.162	
Calories	0.709	0.573	0.519	0.015*	0.62	0.831	0.709	0.007*	0.112	
Protein	0.769	0.611	0.385	0.029*	0.678	0.873	0.519	0.008*	0.121	
Fat	0.65	0.811	0.117	0.025*	0.852	0.79	0.915	0.08	0.011*	
Carbohydrate	0.555	0.689	0.831	0.062	0.474	0.611	0.873	0.038*	0.279	
Fiber	0.915	0.631	0.894	0.036*	0.545	0.669	0.811	0.107	0.104	

*, statistically significant (P<0.05). PKU, phenylketonuria; 25(OH)D₃, 25-hydroxyvitamin D₃; Phe, phenylalanine; Tyr, tyrosine; C0, free carnitine.

which affect the synthesis of short-chain fatty acids (6). We need to analyze the changes of intestinal flora in combination with many environmental factors.

Based on microbial function prediction using the PICRUSt analysis, we focused on glutamate metabolism, as we predicted that it would be decreased in the PKU group. Glutamate metabolism involves enterocyte proliferation, suppresses proinflammatory signaling pathways, confers protection against apoptosis and cellular stresses during normal and pathological conditions, including autism and other conditions or diseases related to the central nervous system (28,29). During the follow-up of our PKU cohort, we found that 27% of the children exhibited cognitive impairment and developmental delay even under strict Phe-restricted diets. Further, our data were consistent with those of a systematic review (25–33%) (30). In relation to the role of glutamate in the gut, future studies of neurotransmitter metabolomics need to be conducted to confirm the status of glutamate metabolism in the intestine of children with PKU.

Limitations

We found evidence of a strong negative correlation between the genus *Bacteroides* and blood Phe levels in our PKU group, which corresponds to the low abundance of this bacteria described earlier. As bacterial abundance is readily affected by environmental factors, we were unable to determine whether the low abundance of this bacteria is a cause or a consequence of blood Phe level in our cohort. In addition, this study comprised patients with a specific ethnic and genetic background. Future studies should increase the sample size and add different races and a mild hyperphemia group as control groups to verify the level of genus *Bacteroides* in different groups. In addition, we can better explain the relationship between gut microbiome and diet habits, genetic background, diet treatment and the disease itself.

Conclusions

Through high-throughput sequencing of the 16S rRNA gene, we discovered that the genus *Bacteroides* were not only in extremely low abundance in Uygur patients with PKU, but were also negatively correlated with blood Phe level. Our findings predicted a decreased ability of glutamate metabolism in the PKU group. Additionally, in PKU, because the treatment interventions are based on long-term or lifelong customized dietary plans. According to the only study on adult with PKU, the impact of the PKU

diet and treatment over the course of a patient's lifetime remains an unknown. Interestingly, these studies (include ours) all indicated significant differences between the PKU and the control group in glucose metabolism or synthesis, which could be the direction of follow-up studies. In future studies, and as part of efforts to increase the sample size, we will refine the blood and diet indicators related to glucose metabolism to better understand the underlying causes of and confirm the reasons for abnormal glucose metabolism. We will also perform microbiota metabolomic research to investigate glutamate levels in the gut microbiota of children with PKU who have developmental delays.

Acknowledgments

We are very grateful to the patients and their families, the clinicians who took care of the patients, and our team members who contributed to this study.

Funding: None.

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <https://dx.doi.org/10.21037/tp-21-426>

Data Sharing Statement: Available at <https://dx.doi.org/10.21037/tp-21-426>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/tp-21-426>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Board of the People's Hospital of Xinjiang Uyghur Autonomous Region (KY2021031018), and written informed consent was obtained from the parents of the participants for the publication of this study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Lowe TB, DeLuca J, Arnold GL. Similarities and differences in key diagnosis, treatment, and management approaches for PAH deficiency in the United States and Europe. *Orphanet J Rare Dis* 2020;15:266.
2. Cazzorla C, Bensi G, Biasucci G, et al. Living with phenylketonuria in adulthood: the PKU ATTITUDE study. *Mol Genet Metab Rep* 2018;16:39-45.
3. Bilder DA, Noel JK, Baker ER, et al. Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria. *Dev Neuropsychol* 2016;41:245-60.
4. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. *N Engl J Med* 2016;375:2369-79.
5. Pinheiro de Oliveira F, Mendes RH, Dobbler PT, et al. Phenylketonuria and gut microbiota: a controlled study based on next-generation sequencing. *PLoS One* 2016;11:e0157513.
6. Bassanini G, Ceccarani C, Borgo F, et al. Phenylketonuria diet promotes shifts in firmicutes populations. *Front Cell Infect Microbiol* 2019;9:101.
7. Mancilla VJ, Mann AE, Zhang Y, et al. The adult phenylketonuria (PKU) gut microbiome. *Microorganisms* 2021;9:530.
8. Su Y, Wang H, Rejiafu N, et al. The molecular epidemiology of hyperphenylalaninemia in Uyghur population: incidence from newborn screening and mutational spectra. *Ann Transl Med* 2019;7:258.
9. Hillert A, Anikster Y, Belanger-Quintana A, et al. The genetic landscape and epidemiology of phenylketonuria. *Am J Hum Genet* 2020;107:234-50.
10. World Health Organization. WHO child growth standards and the identification of severe acute malnutrition in infants and children: a joint statement by the World Health Organization and the United Nations Children's Fund. 2009. Available online: https://apps.who.int/iris/bitstream/handle/10665/44129/9789241598163_eng.pdf?ua=1
11. Yang YX Ge YK. *Encyclopedia of nutrition science*. 2nd ed. Beijing: People's Medical Publishing House, 2019.
12. Subspecialty Group of Newborn Screening, Society of Birth Defects Prevention and Control, Chinese Preventive Medicine Association; Subspecialty Group of Clinical Nutrition, the Society of Pediatrics, Chinese Medical Association; Subspecialty Committee of Clinical Biochemistry and Genetics, the Society of Medical Genetics, Chinese Medical Doctor Association, et al. Consensus statement on dietary treatment and nutritional management for phenylalanine hydroxylase deficiency. *Zhonghua Er Ke Za Zhi* 2019;57:405-9.
13. Chen S, Zhou Y, Chen Y, et al. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* 2018;34:i884-90.
14. Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics* 2011;27:2957-63.
15. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. *Nat Methods* 2013;10:996-8.
16. Wang Q, Garrity GM, Tiedje JM, et al. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol* 2007;73:5261-7.
17. Mallon CA, Le Roux X, van Doorn GS, et al. The impact of failure: unsuccessful bacterial invasions steer the soil microbial community away from the invader's niche. *ISME J* 2018;12:728-41.
18. Mallon CA, Poly F, Le Roux X, et al. Resource pulses can alleviate the biodiversity-invasion relationship in soil microbial communities. *Ecology* 2015;96:915-26.
19. Frost F, Storck LJ, Kacprowski T, et al. A structured weight loss program increases gut microbiota phylogenetic diversity and reduces levels of *Collinsella* in obese type 2 diabetics: a pilot study. *PLoS One* 2019;14:e0219489.
20. Gomez-Arango LF, Barrett HL, Wilkinson SA, et al. Low dietary fiber intake increases *Collinsella* abundance in the gut microbiota of overweight and obese pregnant women. *Gut Microbes* 2018;9:189-201.
21. Karlsson FH, Fåk F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. *Nat Commun* 2012;3:1245.
22. Cheng F. *Epidemiology Study of Risk Factors and Genetic Susceptibility of Han and Uigur Breast Cancer in Xinjiang*. Urumqi: Xinjiang Medical University, 2010.
23. Luis AS, Briggs J, Zhang X, et al. Dietary pectic glycans are degraded by coordinated enzyme pathways in human colonic *Bacteroides*. *Nat Microbiol* 2018;3:210-9.
24. Ndeh D, Rogowski A, Cartmell A, et al. Complex pectin metabolism by gut bacteria reveals novel catalytic functions. *Nature* 2017;544:65-70.

25. Everard A, Belzer C, Geurts L, et al. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* 2013;110:9066-71.
26. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. *World J Gastroenterol* 2014;20:7381-91.
27. Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. *Microbiome* 2019;7:91.
28. Perna S, Alalwan TA, Alaali Z, et al. The role of glutamine in the complex interaction between gut microbiota and health: a narrative review. *Int J Mol Sci* 2019;20:5232.
29. Wang M, Wan J, Rong H, et al. Alterations in gut glutamate metabolism associated with changes in gut microbiota composition in children with autism spectrum disorder. *mSystems* 2019;4:e00321-18.
30. Burlina AP, Lachmann RH, Manara R, et al. The neurological and psychological phenotype of adult patients with early-treated phenylketonuria: a systematic review. *J Inherit Metab Dis* 2019;42:209-19.

(English Language Editor: L. Huleatt)

Cite this article as: Su Y, Shadike Q, Wang M, Jiang H, Liu W, Liu J, Tuerdi R, Zhou W, Li L. A low abundance of genus *Bacteroides* in gut microbiota is negatively correlated with blood phenylalanine levels in Uygur patients with phenylketonuria. *Transl Pediatr* 2021;10(10):2521-2532. doi: 10.21037/tp-21-426